INDP: Indaptus Therapeutics, Inc. Stock

by  •  • Comments Off on INDP: Indaptus Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 6.97
Enterprise Value ($M) 1.18
Book Value ($M) 3.94
Book Value / Share 0.27
Price / Book 1.77
NCAV ($M) 3.22
NCAV / Share 0.22
Price / NCAV 2.16

Profitability (mra)
Return on Invested Capital (ROIC) -3.72
Return on Assets (ROA) -1.37
Return on Equity (ROE) -1.60

Liquidity (mrq)
Quick Ratio 1.95
Current Ratio 1.95

Balance Sheet (mrq) ($M)
Current Assets 6.62
Assets 7.34
Liabilities 3.39
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -15.37
Net Income -15.02

Cash Flow Statement (mra) ($M)
Cash From Operations -12.32
Cash from Investing 0.00
Cash from Financing 4.75

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-18 13G YA II PN, Ltd. 9.99
11-26 13D/A Meckler Jeffrey A 6.90 10.76

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 2,054 17,166 11.97
2025-04-16 8,706 18,412 47.28
2025-04-15 8,396 33,674 24.93
2025-04-14 1,848 30,401 6.08

(click for more detail)

Similar Companies
IMNN – Imunon, Inc. IMTX – Immatics N.V.
INAB – IN8bio, Inc. INKT – MiNK Therapeutics, Inc.
INM – InMed Pharmaceuticals Inc.


Financial data and stock pages provided by
Fintel.io